Rydex Health Care Fund Class C RYHCX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 103.80  /  +0.14 %
  • Total Assets 21.7M
  • Adj. Expense Ratio
    2.400%
  • Expense Ratio 2.400%
  • Distribution Fee Level High
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.00
  • Turnover 244%

USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0

Morningstar’s Analysis RYHCX

Will RYHCX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Rydex Health Care C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHCX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 24.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

4.07 796,146
Healthcare

Johnson & Johnson

3.40 665,741
Healthcare

AbbVie Inc

2.94 575,405
Healthcare

UnitedHealth Group Inc

2.59 506,811
Healthcare

Merck & Co Inc

2.42 473,147
Healthcare

Thermo Fisher Scientific Inc

2.15 420,962
Healthcare

Amgen Inc

1.94 378,997
Healthcare

Abbott Laboratories

1.93 377,560
Healthcare

Gilead Sciences Inc

1.67 327,218
Healthcare

Bristol-Myers Squibb Co

1.61 315,774
Healthcare

Sponsor Center